secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-09-08T23:59:59+00:00
Accession:  0001664710-25-000081
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros reports KER-065 Phase 1 data: BMD improvements sustained to Day 141
-------------------------------------------------------------------------

- Phase 1 trial in healthy males showed no dose-limiting toxicities or serious adverse events.
- Whole body BMD improved at Day 85 and was sustained through Day 141 (three months post-last dose).
- Lumbar spine BMD increased after three doses and remained elevated through Day 141.
- Bone biomarker changes indicated increased formation and reduced resorption, consistent with tissue-level effects.
- Data presented at ASBMR 2025 support potential in Duchenne muscular dystrophy and bone disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000081/0001664710-25-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000081/kros-20250908.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer